Dynamic Analysis Of Intestinal Microbiota From IBS-D Patient And Restoration With Prebiotic

Microbiota imbalance was one of the reasons of diarrheal irritable bowel(IBS-D).The specific changes of gut microbiota was not particularly clear.Using microecologics clinically was effective in the management of gastrointestinal diseases through improve intestina microbiota.This study aimed to reveal the pathogenesis of IBS-D and provide experimental basis for the clinical use of microecologics.Objective: Monitoring the dynamic change of intestinal flora in the real time to research IBS-D.Clinical validated the identified microflora of IBS-D as a potential biomarker.Functional oligosaccharide(FOS)promoted the recovery of gut microbiota.Methods: Fecal samples from a IBS-D patient were continuously collected within a month.Then the same patient took 6 grams FOS per day,2 weeks later,fecal samples were collected again during 12 days.Totally fecal bacteria DNA was extracted.Denaturing gradient gel electrophores(DGGE)was done to detect the changes of gut microbiota diversity.Fifteen clinical samples and 10 healthy control samples were collected,and high-throughput sequencing was utilized to verify the general rule.Results: During illness period,the patient's gut microbiota as a whole showed less instability compared with the healthy individuals,the diversity of gut microbiota and amount of Faecalibacterium prausnitziand were less,while after taking FOS found increasing in amount of Faecalibacterium prausnitzi,as well as decreasing the symptom conditions.In order to verify the relationship between the detected characteristic bacteria and IBS-D disease,a higher sensitivity high throughput sequencing techology was used to detect the fecal samples of 15 clinical patients.The results showed the patient's gut microbiota was imbalance.Probiotics Faecalibacterium prausnitzi decreased and bad bacteria increased.Conclusions: The imbalance of gut microbiota was linked to IBS-D,and functional FOS could improve the condition of IBS-D patients by enhancing the overall stability of gut microbiota and increasing Faecalibacterium prausnitzi.This study is to provide evidence for the treatment of IBS-D in clinically.